0001209191-17-014829.txt : 20170227
0001209191-17-014829.hdr.sgml : 20170227
20170227165447
ACCESSION NUMBER: 0001209191-17-014829
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170223
FILED AS OF DATE: 20170227
DATE AS OF CHANGE: 20170227
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INCYTE CORP
CENTRAL INDEX KEY: 0000879169
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 943136539
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
BUSINESS PHONE: 3024986700
MAIL ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE CORP
DATE OF NAME CHANGE: 20030318
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE GENOMICS INC
DATE OF NAME CHANGE: 20000710
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930902
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FRIEDMAN PAUL A
CENTRAL INDEX KEY: 0001236927
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12400
FILM NUMBER: 17642641
MAIL ADDRESS:
STREET 1: C/O INCYTE CORPORATION
STREET 2: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-02-23
0
0000879169
INCYTE CORP
INCY
0001236927
FRIEDMAN PAUL A
1801 AUGUSTINE CUT-OFF
WILMINGTON
DE
19803
1
0
0
0
Common Stock
2017-02-23
4
M
0
50000
18.32
A
347518
D
Common Stock
2017-02-23
4
S
0
50000
120.32
D
297518
D
Non-Qualified Stock Option (right to buy)
18.32
2017-02-23
4
M
0
50000
0.00
D
2020-02-08
Common Stock
50000
144542
D
Represents weighted average sale price. Actual sale prices ranged from $120.00 - $120.64.
Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated.
Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.
/s/ Paul A. Friedman
2017-02-27